Loading
Loading
Growth Hormone & Secretagogues · 5mg
Janoshik-tested · 10 vials per kit
CJC-1295 with DAC is a long-acting GHRH analog studied in preclinical and clinical research for its growth hormone-releasing properties. Its Drug Affinity Complex (DAC) technology enables a single dose to stimulate growth hormone secretion for several days, reducing dosing frequency. Research has explored applications in growth hormone deficiency, aging-related GH decline, and improvements in bone density, muscle strength, and skin elasticity.
≥98%
Purity
Lyophilised
Format
2–3 wks
Arrival
Don't want to wait 3 weeks?
Check local stock — weekday same/next-day delivery available.
Chemical Properties
Need to work out your dose?
Use our reconstitution calculator — syringe units in seconds.
Research Use Only — Disclaimer
This product is intended solely as a research chemical for laboratory and scientific study purposes only. It is not approved by the TGA or any regulatory body for human or animal consumption, therapeutic use, or clinical application. The information provided on this website is for educational purposes only. Handling must be limited to suitably qualified professionals operating within applicable laws and regulations. This product is not classified as a drug, food, cosmetic, or medicinal product and must not be used or labelled as such. By purchasing, you confirm you are a qualified research professional and accept full responsibility for compliance with all relevant laws in your jurisdiction.
CJC-1295 DAC
GHRH Analog with Drug Affinity Complex
CJC-1295 with DAC is a modified analog of growth hormone-releasing hormone (GHRH/GRF(1-44)), the hypothalamic neuropeptide that stimulates pituitary GH secretion. The DAC (Drug Affinity Complex) modification attaches a maleimido propionic acid group to lysine at position 28, enabling covalent binding to cysteine-34 of circulating albumin. This extends half-life from minutes (endogenous GHRH) to approximately 6-8 days, permitting once-weekly dosing in research protocols.
CJC-1295 DAC acts at GHRH receptors on somatotroph cells of the anterior pituitary to stimulate GH synthesis and release in a pulsatile pattern. The sustained albumin-bound depot maintains GHRH receptor occupancy over days, producing prolonged elevation in both GH and downstream IGF-1 levels. Unlike exogenous GH administration, this stimulates physiological GH release from the pituitary, preserving some feedback regulation.
Research has examined CJC-1295 DAC for GH-axis support in age-related GH decline, body composition research (lean mass preservation, visceral fat reduction), post-operative recovery, and IGF-1 upregulation. It is frequently studied in combination with ghrelin mimetics (Ipamorelin, GHRP-2) as these peptides act on the complementary ghrelin receptor pathway to provide synergistic GH pulse amplification.
Key References
For research reference only. All information pertains to preclinical or published human trial data. Not intended as medical advice. This product is for research use only.
Don't have supplies? Grab them while you're here.
